Annual Accounts Receivable
$607.00 K
-$198.00 K-24.60%
December 31, 2024
Summary
- As of March 8, 2025, EYPT annual accounts receivable is $607.00 thousand, with the most recent change of -$198.00 thousand (-24.60%) on December 31, 2024.
- During the last 3 years, EYPT annual accounts receivable has fallen by -$17.75 million (-96.69%).
- EYPT annual accounts receivable is now -96.69% below its all-time high of $18.35 million, reached on December 31, 2021.
Performance
EYPT Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Accounts Receivable
$607.00 K
+$229.00 K+60.58%
December 31, 2024
Summary
- As of March 8, 2025, EYPT quarterly accounts receivable is $607.00 thousand, with the most recent change of +$229.00 thousand (+60.58%) on December 31, 2024.
- Over the past year, EYPT quarterly accounts receivable has increased by +$229.00 thousand (+60.58%).
- EYPT quarterly accounts receivable is now -97.62% below its all-time high of $25.46 million, reached on September 30, 2014.
Performance
EYPT Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Accounts Receivable Formula
Accounts Receivable = Total Credit Sales − Amount Collected from Credit Sales
EYPT Accounts Receivable Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -24.6% | +60.6% |
| 3 y3 years | -96.7% | -96.1% |
| 5 y5 years | -94.7% | -96.1% |
EYPT Accounts Receivable Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -96.7% | at low | -97.3% | +60.6% |
| 5 y | 5-year | -96.7% | at low | -97.3% | +60.6% |
| alltime | all time | -96.7% | +141.8% | -97.6% | +141.8% |
EyePoint Pharmaceuticals Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $607.00 K(-24.6%) | $607.00 K(+60.6%) |
| Sep 2024 | - | $378.00 K(-72.5%) |
| Jun 2024 | - | $1.38 M(-54.4%) |
| Mar 2024 | - | $3.02 M(+274.5%) |
| Dec 2023 | $805.00 K(-94.8%) | $805.00 K(+66.7%) |
| Sep 2023 | - | $483.00 K(-95.6%) |
| Jun 2023 | - | $10.95 M(+5.1%) |
| Mar 2023 | - | $10.42 M(-32.8%) |
| Dec 2022 | $15.50 M(-15.5%) | $15.50 M(-25.7%) |
| Sep 2022 | - | $20.88 M(-7.6%) |
| Jun 2022 | - | $22.59 M(+15.3%) |
| Mar 2022 | - | $19.59 M(+6.7%) |
| Dec 2021 | $18.35 M(+94.2%) | $18.35 M(+34.9%) |
| Sep 2021 | - | $13.60 M(-10.0%) |
| Jun 2021 | - | $15.11 M(+22.5%) |
| Mar 2021 | - | $12.33 M(+30.5%) |
| Dec 2020 | $9.45 M(-16.8%) | $9.45 M(+0.6%) |
| Sep 2020 | - | $9.39 M(+27.8%) |
| Jun 2020 | - | $7.35 M(-48.9%) |
| Mar 2020 | - | $14.39 M(+26.6%) |
| Dec 2019 | $11.37 M(+1713.1%) | $11.37 M(+28.4%) |
| Sep 2019 | - | $8.86 M(-7.7%) |
| Jun 2019 | - | $9.60 M(+325.1%) |
| Mar 2019 | - | $2.26 M(+361.8%) |
| Dec 2018 | $627.00 K(+77.6%) | - |
| Sep 2018 | - | $489.00 K(+38.5%) |
| Jun 2018 | $353.00 K(+40.6%) | $353.00 K(-26.2%) |
| Mar 2018 | - | $478.00 K(+66.0%) |
| Dec 2017 | - | $288.00 K(+0.3%) |
| Sep 2017 | - | $287.00 K(+14.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2017 | $251.00 K(-48.6%) | $251.00 K(-16.3%) |
| Mar 2017 | - | $300.00 K(-34.4%) |
| Dec 2016 | - | $457.00 K(-1.1%) |
| Sep 2016 | - | $462.00 K(-5.3%) |
| Jun 2016 | $488.00 K(-21.5%) | $488.00 K(+3.4%) |
| Mar 2016 | - | $472.00 K(-17.6%) |
| Dec 2015 | - | $573.00 K(+0.7%) |
| Sep 2015 | - | $569.00 K(-8.5%) |
| Jun 2015 | $622.00 K(+20.3%) | $622.00 K(+44.7%) |
| Mar 2015 | - | $430.00 K(-40.9%) |
| Dec 2014 | - | $727.00 K(-97.1%) |
| Sep 2014 | - | $25.46 M(+4825.0%) |
| Jun 2014 | $517.00 K(-13.4%) | $517.00 K(-15.7%) |
| Mar 2014 | - | $613.00 K(-3.6%) |
| Dec 2013 | - | $636.00 K(-42.8%) |
| Sep 2013 | - | $1.11 M(+86.3%) |
| Jun 2013 | $597.00 K(-38.3%) | $597.00 K(-42.3%) |
| Mar 2013 | - | $1.03 M(+9.2%) |
| Dec 2012 | - | $948.00 K(+1.1%) |
| Sep 2012 | - | $938.00 K(-3.0%) |
| Jun 2012 | $967.00 K(-13.0%) | $967.00 K(-1.8%) |
| Mar 2012 | - | $985.00 K(-3.1%) |
| Dec 2011 | - | $1.02 M(+40.5%) |
| Sep 2011 | - | $723.00 K(-13.1%) |
| Mar 2011 | - | $832.00 K(-25.1%) |
| Jun 2010 | $1.11 M(+12.7%) | $1.11 M(+26.4%) |
| Mar 2009 | - | $879.00 K(-24.4%) |
| Sep 2008 | - | $1.16 M(+17.8%) |
| Jun 2008 | $986.00 K(+0.3%) | $986.00 K(-39.2%) |
| Jun 2007 | $983.00 K | - |
| Dec 2006 | - | $1.62 M |
FAQ
- What is EyePoint Pharmaceuticals annual accounts receivable?
- What is the all time high annual accounts receivable for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals annual accounts receivable year-on-year change?
- What is EyePoint Pharmaceuticals quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for EyePoint Pharmaceuticals?
- What is EyePoint Pharmaceuticals quarterly accounts receivable year-on-year change?
What is EyePoint Pharmaceuticals annual accounts receivable?
The current annual accounts receivable of EYPT is $607.00 K
What is the all time high annual accounts receivable for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high annual accounts receivable is $18.35 M
What is EyePoint Pharmaceuticals annual accounts receivable year-on-year change?
Over the past year, EYPT annual accounts receivable has changed by -$198.00 K (-24.60%)
What is EyePoint Pharmaceuticals quarterly accounts receivable?
The current quarterly accounts receivable of EYPT is $607.00 K
What is the all time high quarterly accounts receivable for EyePoint Pharmaceuticals?
EyePoint Pharmaceuticals all-time high quarterly accounts receivable is $25.46 M
What is EyePoint Pharmaceuticals quarterly accounts receivable year-on-year change?
Over the past year, EYPT quarterly accounts receivable has changed by +$229.00 K (+60.58%)